Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21543585 | 0.88 | ALDH1A1 (0.33) | TTRALBHTTALDH1A1CYP2A6 | |
| SCHEMBL22014717 | 0.86 | TTR (0.44) | TTRALBGABRA1GABRB1MEN1 | |
| SCHEMBL22014711 | 0.83 | HTT (0.38) | HTTALDH1A1CYP2A6 | |
| SCHEMBL19507327 | 0.82 | TTR (0.41) | TTRALBGABRA1GABRB1MEN1 | |
| SCHEMBL22014708 | 0.82 | — | — | |
| SCHEMBL2154261 | 0.81 | TTR (0.39) | TTRALBGABRA1GABRB1MEN1 | |
| SCHEMBL23320036 | 0.80 | CHRNA1 (0.34) | — | |
| SCHEMBL22899690 | 0.79 | TTR (0.38) | TTRALBGABRA1GABRB1MEN1 | |
| SCHEMBL19505731 | 0.79 | TTR (0.38) | TTRALBGABRA1GABRB1MEN1 | |
| SCHEMBL2155740 | 0.79 | TTR (0.38) | TTRALBGABRA1GABRB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12122918-B2 | Drug that reacts with acrolein, use thereof and novel compound | RIKEN (JP) | 2024-10-22 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184623-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-0661350-B1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON CATALYTIC CHEM IND (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-5968688-A | RESINS AND DYES FOR COLOR FILTERS | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5817843-A | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0833203-A1 | Color filter grade photosensitive resin coloring composition, and color filter using the same | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-04-01 | — | — | EP | disclosed |
| US-5608091-A | SHEETS FOR HEAT EXCHANGING AND OPTICAL RECORDING MATERIAL | NIPPON SHOKUBAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0661350-A1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | TTR 1161/4885ALB 1427/4885GABRA1 2257/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | TTR 630/4885ALB 731/4885GABRA1 3978/4885 |
| US-12122918-B2 | Drug that reacts with acrolein, use thereof and novel compound | ACR, CYP2E1, CES2 | TTR 2331/4885ALB 388/4885GABRA1 718/4885 |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | TTR 630/4885ALB 731/4885GABRA1 3978/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | TTR 630/4885ALB 731/4885GABRA1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.